CRVS Corvus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRVS

Price (delayed)

$1.64

Market cap

$80.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$62.01M

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells ...

Highlights
The debt has contracted by 41% YoY and by 15% from the previous quarter
The EPS has increased by 26% YoY and by 24% QoQ
The quick ratio has grown by 23% YoY but it has contracted by 6% from the previous quarter
Corvus Pharmaceuticals's equity has decreased by 32% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corvuspharma.com
Peers: OMGA

Key stats

What are the main financial stats of CRVS
Market
Shares outstanding
49.04M
Market cap
$80.42M
Enterprise value
$62.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.81
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$30.19M
EBITDA
-$29.98M
Free cash flow
-$26.33M
Per share
EPS
-$0.64
Free cash flow per share
-$0.54
Book value per share
$0.9
Revenue per share
$0
TBVPS
$1.06
Balance sheet
Total assets
$51.94M
Total liabilities
$7.65M
Debt
$1.69M
Equity
$44.29M
Working capital
$25.8M
Liquidity
Debt to equity
0.04
Current ratio
4.53
Quick ratio
4.41
Net debt/EBITDA
0.61
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.1%
Return on equity
-60.8%
Return on invested capital
-75.4%
Return on capital employed
-67.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
-5.75%
1 week
9.33%
1 month
10.81%
1 year
57.69%
YTD
92.94%
QTD
12.33%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.4M
Net income
-$30.19M
Gross margin
N/A
Net margin
N/A
The operating income rose by 31% year-on-year and by 23% since the previous quarter
Corvus Pharmaceuticals's net income has increased by 26% YoY and by 23% QoQ

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 26% YoY and by 24% QoQ
The price to book (P/B) is 39% higher than the 5-year quarterly average of 1.3 and 39% higher than the last 4 quarters average of 1.3
Corvus Pharmaceuticals's equity has decreased by 32% YoY and by 10% QoQ

Efficiency

How efficient is Corvus Pharmaceuticals business performance
The ROE is down by 24% year-on-year but it is up by 15% since the previous quarter
The company's return on assets fell by 20% YoY but it rose by 13% QoQ
Corvus Pharmaceuticals's return on invested capital has increased by 14% QoQ and by 4.8% YoY

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
Corvus Pharmaceuticals's total liabilities has shrunk by 51% YoY and by 11% QoQ
The total assets has contracted by 35% YoY and by 11% from the previous quarter
The debt is 96% less than the equity
The debt has contracted by 41% YoY and by 15% from the previous quarter
Corvus Pharmaceuticals's equity has decreased by 32% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.